Bristol/Agios AML’s Idhifa Fails In Phase III, But Approval Seems Secure

 
• By Mandy Jackson
  
microscope
Idhifa missed the overall survival endpoint in Phase III
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards